STOCK TITAN
  1. Home
  2. News
  3. PLSE

Pulse Biosciences, Inc - PLSE STOCK NEWS

Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.

Pulse Biosciences, Inc. (PLSE) is a pioneering clinical-stage electroceutical company focused on the commercial application of its proprietary Nano-Pulse Stimulation (NPS) technology. Headquartered in Hayward, CA, the company's core mission is to leverage this novel technology to improve and extend patient lives, addressing the distinct needs of patients and physicians alike.

Nano-Pulse Stimulation Technology

NPS is a cutting-edge, non-thermal, drug-free energy-based technology that utilizes ultra-short nanosecond electrical pulses to impact cell membranes and intracellular structures. This method promotes unique cellular behaviors and can induce specific immune responses, opening up a myriad of therapeutic possibilities. Unlike conventional treatments, NPS delivers electrical pulses in billionths of a second, providing targeted effects without damaging surrounding tissues.

Applications and Innovations

Pulse Biosciences is actively exploring the potential of its NPS technology across various medical fields. Key areas of investigation include immuno-oncology, where NPS may be used to treat cancer by modulating the immune system's response, and dermatology, for treatments that require precise, non-invasive interventions. The technology's unique biologic effects position it as a promising solution for conditions lacking optimal treatments.

Recent Achievements and Projects

The company has made significant strides in both preclinical and clinical studies, demonstrating the safety and efficacy of NPS technology. Recent projects have focused on refining device capabilities, enhancing treatment protocols, and expanding the scope of applications. Partnerships with leading medical institutions and ongoing collaborations with researchers underscore Pulse Biosciences' commitment to innovation.

Financial Condition

Pulse Biosciences generates substantial revenue primarily from the sale of its systems in North America. The company continues to invest in research and development to further advance its technology and explore new market opportunities.

For those looking to stay updated on the latest developments, performance, and news related to Pulse Biosciences, Inc., StockTitan provides a comprehensive and timely resource.

News

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) announced business updates and financial results for Q4 and full year 2023. Key highlights include FDA clearance for CellFX nsPFA Percutaneous Electrode, positive clinical data on benign thyroid nodules, exceptional lesion quality in cardiac catheter study, and FDA submission for Cardiac Clamp. The company plans a rights offering and universal shelf filing. Financially, GAAP costs increased driven by stock-based compensation, while non-GAAP costs rose to support product portfolio development. Cash and cash equivalents decreased to $44.4 million in Dec 2023. Full-year GAAP net loss was ($42.2) million, with non-GAAP net loss at ($33.8) million. The company will host a conference call on March 28, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
earnings
-
News

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) plans to initiate a rights offering of up to $60 million worth of units, consisting of one share of Common Stock and warrants to purchase another share. The subscription price per unit will be either $10 or the volume weighted average price of the company's stock over 10 trading days. The offering, if fully subscribed, could result in gross proceeds of $60 million with additional proceeds of up to $66 million from warrant exercises. The Company's Executive Chairman has expressed support for the offering. The rights offering will be registered with the SEC via Form S-3.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
none
-
News

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) will report financial results for Q4 and full year 2023 on March 28, 2024, showcasing its CellFX Nanosecond Pulsed Field Ablation™ technology. Investors can join the conference call or watch the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
earnings
News

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) receives FDA clearance for CellFX nsPFA Percutaneous Electrode System, a novel technology for soft tissue ablation in surgical procedures. The system aims to provide nonthermal removal of cellular tissue with minimal damage to noncellular structures, offering a promising treatment option for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
clinical trial
-
News

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Rhea-AI Summary
Pulse Biosciences (PLSE) announces positive 60-day post-procedure evaluations for initial patients in the CellFX nsPFA 360° Cardiac Catheter First-In-Human Feasibility Study. The findings reveal favorable durable pulmonary vein isolation data, validating the unique nsPFA AF catheter solution. Dr. Vivek Reddy expresses optimism about the technology's potential, emphasizing ease-of-use, speed, and versatility. Pulse Biosciences aims to reshape atrial fibrillation treatment with the CellFX nsPFA 360° Cardiac Catheter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.56%
Tags
none
-
News

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) will feature its CellFX Nanosecond Pulsed Field (nsPFA) technology in a podium presentation at the 29th Annual AF Symposium in Boston, Massachusetts. The presentation will focus on the preliminary findings from the Company’s CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study and will be presented by Prof. Petr Neužil and Dr. Vivek Reddy. The technology has shown promise in the treatment of atrial fibrillation, with positive feedback from the initial procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
none
News

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) Files 510(k) Pre-market Notification for CellFX nsPFA Cardiac Clamp with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.97%
Tags
none
-
News

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) Completes First-in-Human Feasibility Study for Atrial Fibrillation Treatment with CellFX nsPFA Cardiac Catheter
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
none
-
News

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Rhea-AI Summary
Pulse Biosciences (PLSE) filed a premarket notification 510(k) to the U.S. FDA for its CellFX nsPFA percutaneous electrode, designed for non-cardiac applications. The filing was made earlier than expected, showcasing the efficiency of the FDA's new electronic submission platform. The FDA will conduct its substantive review, with a goal to complete it within 90 calendar days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
none
News

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
Pulse Biosciences, Inc. (PLSE) to Present at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences

FAQ

What is the current stock price of Pulse Biosciences (PLSE)?

The current stock price of Pulse Biosciences (PLSE) is $16.12 as of November 21, 2024.

What is the market cap of Pulse Biosciences (PLSE)?

The market cap of Pulse Biosciences (PLSE) is approximately 1.0B.

What is Pulse Biosciences, Inc.?

Pulse Biosciences, Inc. is a clinical-stage electroceutical company focused on commercializing its proprietary Nano-Pulse Stimulation technology.

What is Nano-Pulse Stimulation (NPS) technology?

NPS is a non-thermal, drug-free energy-based technology that uses nanosecond electrical pulses to affect cell membranes and intracellular structures.

What are the primary applications of NPS technology?

NPS technology is being investigated for use in immuno-oncology and dermatology, among other medical fields.

Where is Pulse Biosciences, Inc. headquartered?

The company's headquarters are located in Hayward, CA.

How does NPS technology differ from traditional treatments?

NPS delivers ultra-short electrical pulses that target cells without damaging surrounding tissues, unlike conventional treatments.

What recent achievements has Pulse Biosciences made?

The company has demonstrated the safety and efficacy of NPS in preclinical and clinical studies and is refining its technology.

What are the financial sources for Pulse Biosciences?

The company generates substantial revenue from the sale of its systems, primarily in North America.

How does Pulse Biosciences contribute to medical innovation?

Pulse Biosciences collaborates with leading medical institutions and researchers to advance its NPS technology and explore new applications.

What is the mission of Pulse Biosciences?

The mission is to design, produce, and commercialize Nano-Pulse technology to improve and extend patients' lives.

How can I get the latest updates on Pulse Biosciences?

You can stay informed about the latest developments by following updates on platforms like StockTitan.

Stock PLSE logo
Pulse Biosciences, Inc

Nasdaq:PLSE

PLSE Rankings

#2554 Ranked by Market Cap
N/A Ranked by Dividends

PLSE Stock Data

1.00B
17.26M
71.93%
9.32%
4.12%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
HAYWARD